Regeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 Trial
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study.
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The Phase 1, open-label study titled “A Phase 1, Open-Label, Dose-Escalation Study of BPX-601, an Anti-PSCA CAR T Cell Drug Product, in Relapsed/Refractory Metastatic Castration-Resistant Prostate Cancer” will test a new cell therapy in men whose prostate cancer has returned and spread. The goal is to find a safe dose and get an early read on how well it may control disease that no longer responds to standard hormone therapy.
The treatment, BPX-601, is a CAR T-cell therapy made from each patient’s own immune cells. These reprogrammed cells are designed to seek and destroy prostate cancer cells that carry a target on their surface, aiming to offer a new option where current drugs have limited effect.
The trial is interventional and uses a single treatment group, with all enrolled patients receiving BPX-601 under the same plan. There is no random assignment or placebo, and no blinding, so doctors and patients know what is being given, which is typical for first-in-human safety studies focused mainly on treatment impact.
The study was first submitted on 14 April 2026, marking the start of the regulatory review and site setup process. The last update was posted on 28 May 2026, signaling that the plan has been recently refreshed, though enrollment has not yet begun and primary and final completion dates are still ahead.
For investors, this early-stage update highlights Regeneron’s push into cell therapy and solid tumors, areas where success could open large new markets beyond its core eye and immunology franchises. While Phase 1 results are years away and clinical risk remains high, visible progress may bolster long-term growth narratives and sharpen competition with oncology players pursuing prostate cancer cell therapies.
The study remains active in planning and not yet recruiting, with further details and ongoing updates available on the ClinicalTrials portal.
To learn more about REGN’s potential, visit the Regeneron Pharmaceuticals drug pipeline page.
